Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the rate and extent of absorption of
mesalamine-sodium hyaluronate 200 mg-28.75 mg delayed-release capsule (IBD98-M, Test) versus
Delzicol 400 mg delayed-release capsule (mesalamine Reference), administered as a single oral
dose of 2 x 200 mg-28.75 mg delayed-release capsule (total dose of 400 mg-57.50 mg) or 1 x
400 mg delayed-release capsule under fasting conditions.